CTLA4 antagonists in phase I and phase II clinical trials, current status  and  future perspectives for cancer therapy

References

• van Hooren L, Sandin LC, Moskalev I, et al. Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol. 2017;47:385–393.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yang W, Huang Y, et al. Evolving roles for targeting CTLA-4 in cancer immunotherapy. Cell Physiol Biochem. 2018;47:721–734.
   PubMed Web of Science ®Google Scholar
• Rangel-Sosa MM, Aguilar-Córdova E, Rojas-Martinez A. Immunotherapy and gene therapy as novel treatment for cancer. Colomb Med. 2017;48(3):138–147.
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh F, Mohammadi S, Nejatollahi F. Production and evaluation of specific single chain antibodies against CTLA-4 for cancer-targeted therapy. Rep Biochem Mol Biol. 2017;6(1):8–14.
   PubMed Web of Science ®Google Scholar
• Carosella ED, Ploussard G, LeMaoult J, et al. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267–279.
   PubMed Web of Science ®Google Scholar
• Ingram JR, Blomberg OS, Rashidian M, et al. Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci USA. 2018;115(15):3912–3917.
   PubMed Web of Science ®Google Scholar
• Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol. 2015;27(1):3–10.
   PubMed Web of Science ®Google Scholar
• Schneider H, Smith X, Liu H, et al. CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization. Eur J Immunol. 2008;38:40–47.
   PubMed Web of Science ®Google Scholar
• Walker L, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 2015;36(2):63–70.
   PubMed Web of Science ®Google Scholar
• Dariavach P, Mattei MG, Golstein P, et al. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol. 1988;18:1901–1905.
   PubMed Web of Science ®Google Scholar
• Schneider H, Prasad KV, Shoelson SE, et al. CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp Med. 1995;181:351–355.
   PubMed Web of Science ®Google Scholar
• Kosmaczewska A, Ciszak L, Suwalska K, et al. CTLA-4 overexpression in CD19+/CD5+ cells correlates with the level of cell cycle regulators and disease progression in B-CLL patients. Leukemia. 2005;19:301–304.
   PubMed Web of Science ®Google Scholar
• Joshi AD, Hegde GV, Dickinson JD, et al. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:5295–5304.
   PubMed Web of Science ®Google Scholar
• Seliger B, Maio M, Cuaia O, et al. Expression and function of CTLA4 in melanoma. J Clin Oncol. 2013;31:e20040.
   Web of Science ®Google Scholar
• Mao H, Zhang L, Yang Y, et al. New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets. 2010;10:728–736.
   PubMed Web of Science ®Google Scholar
• Huang PY, Guo SS, Zhang Y, et al. Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. Oncotarget. 2016;7:13060–13068.
   PubMedGoogle Scholar
• Salvi S, Fontana V, Boccardo S, et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2012;61:1463–1472.
   PubMed Web of Science ®Google Scholar
• Erfani N, Mehrabadi SM, Ghayumi MA, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2012;77:306–311.
   PubMed Web of Science ®Google Scholar
• Roncella S, Laurent S, Fontana V, et al. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor. Cancer Immunol Immunother. 2016;65:909–917.
   PubMed Web of Science ®Google Scholar
• Erfani N, Haghshenas MR, Hoseini MA, et al. Strong association of CTLA-4 variation (CT60A/G) and CTLA-4 haplotypes with predisposition of Iranians to head and neck cancer. Iran J Immunol. 2012;9:188–198.
   PubMed Web of Science ®Google Scholar
• Song B, Liu Y, Liu J, et al. CTLA-4 +49A>G polymorphism is associated with advanced non-small cell lung cancer prognosis. Respiration. 2011;82:439–444.
   PubMed Web of Science ®Google Scholar
• Karabon L, Pawlak-Adamska E, Tomkiewicz A, et al. Variations in suppressor molecule CTLA-4 gene are related to susceptibility to multiple myeloma in a Polish population. Pathol Oncol Res. 2012;18:219–226.
   PubMed Web of Science ®Google Scholar
• Zheng J, Yu X, Jiang L, et al. Association between the cytotoxic T-lymphocyte antigen 4 +49G > A polymorphism and cancer risk: a meta-analysis. BMC Cancer. 2010;10:522.
   PubMed Web of Science ®Google Scholar
• Liu Z, Song Z, Sun J, et al. Association between CTLA-4 rs231775 polymorphism and hepatocellular carcinoma susceptibility. Int J Clin Exp Pathol. 2015;8:15118–15122.
   PubMed Web of Science ®Google Scholar
• Wang L, Jing F, Su D, et al. Association between CTLA-4 rs231775 polymorphism and risk of colorectal cancer: a meta-analysis. Int J Clin Exp Med. 2015;8:650–657.
   PubMedGoogle Scholar
• Hodi SF, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Gao J, Shi LZ, Zhao H, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167:397–404.
   PubMed Web of Science ®Google Scholar
• Hailmichael Y, Woods A, Fu T, et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018;128:1338–1354.
   PubMed Web of Science ®Google Scholar
• Tallerico R, Cristiani CM, Staaf E, et al. IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncoimmunology. 2016;6:e1261242.
   PubMed Web of Science ®Google Scholar
• Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015;33:74–82.
   PubMed Web of Science ®Google Scholar
• Vargas FA, Furness AJS, Litchfield K, et al. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell. 2018;33:649–663.
   PubMed Web of Science ®Google Scholar
• Soto-Pantoja DR, Wilson AS, Clear KY, et al. Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness. Oncotarget. 2017;8:80545–80559.
   PubMedGoogle Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17:6958–6962.
   PubMed Web of Science ®Google Scholar
• Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34–44.
   PubMed Web of Science ®Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol. 2015;33:3193–3198.
   PubMed Web of Science ®Google Scholar
• Ma C, Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat. 2014;25:401–408.
   PubMed Web of Science ®Google Scholar
• Samara Y, Yu CL, Dasanu CA. Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. J Oncol Pharm Pract. 2018. doi: 10.1177/1078155218755868.
   Google Scholar
• Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965–973.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse effects associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS One. 2016;11:e0160221.
   PubMed Web of Science ®Google Scholar
• Cheng R, Cooper A, Kench J, et al. Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol. 2015;30:657–666.
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.
   PubMed Web of Science ®Google Scholar
• Ahmed T, Pandey R, Shah B, et al. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep. 2015;2015:pii: bcr2014208102.
   Google Scholar
• Tanaka R, Fujisawa Y, Sae I, et al. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Jpn J Clin Oncol. 2017;47:175–178.
   PubMed Web of Science ®Google Scholar
• Fukumoto T, Fujiwara S, Tajima S, et al. Infliximab for severe colitis associated with nivolumab followed by ipilimumab. J Dermatol. 2018;45:e1–e2.
   PubMed Web of Science ®Google Scholar
• Gaudy-Marqueste C, Monestier S, Franques J, et al. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36:77–78.
   PubMed Web of Science ®Google Scholar
• Nayar N, Briscoe K, Fernandez Penas P. Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother. 2016;39:149–152.
   PubMed Web of Science ®Google Scholar
• Appelbaum J, Wells D, Hiatt JB, et al. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer. 2018;6:82.
   PubMed Web of Science ®Google Scholar
• Valpione S, Pasquali S, Campana LG, et al. Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. J Transl Med. 2018;16:94.
   PubMed Web of Science ®Google Scholar
• Weide B, Martens A, Wistuba-Hamprecht K, et al. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Cancer Immunol Immunother. 2017;66:441–449.
   PubMed Web of Science ®Google Scholar
• Merchant MS, Wright M, Baird K, et al. Phase 1 clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22:1364–1370.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141–151.
   PubMed Web of Science ®Google Scholar
• Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011;71:5393–5399.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–133.
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107:4275–4280.
   PubMed Web of Science ®Google Scholar
• Przespolewski A, Szeles A, Wang ES. Advances in immunotherapy for acute myeloid leukemia. Future Oncol. 2018;14:963–978.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
   PubMed Web of Science ®Google Scholar
• Hodi SF, Chesney J, Pavlick AC, et al. Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma. Lancet Oncol. 2016;17:1558–1568.
   PubMed Web of Science ®Google Scholar
• Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672–681.
   PubMed Web of Science ®Google Scholar
• Twabi HAH, Forsyth PAJ, Algazi AP, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study checkMate 204. J Clin Oncol. 2017;35(15_suppl):9507.
   Google Scholar
• Piulats JM, De la Cruz-Merino L, Curiel Garcia M, et al. Phase II multicenter, single arm, open label study of nivolumab (NIVO) in combination with ipilimumab (IPI) as first line in adult patients (pts) with metastatic uveal melanoma (MUM): GEM1402 NCT02626962. J Clin Oncol. 2017;35(15_suppl):9533.
   Google Scholar
• Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17:943–955.
   PubMed Web of Science ®Google Scholar
• Olson D, Luke JJ, Hallmeyer S, et al. Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel). J Clin Oncol. 2018;36(15_suppl):9514.
   Web of Science ®Google Scholar
• Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18:1202–1210.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hodi FS, Thompson JA, et al. Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase Ib KEYNOTE-029 study. Clin Cancer Res. 2018;24:1805–1815.
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Van Akkooi ACJ, Menzies AM, et al. Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo). J Clin Oncol. 2018;36(15_suppl):TPS9606.
   Google Scholar
• Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003;17:1263–1293.
   PubMed Web of Science ®Google Scholar
• Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590–603.
   PubMed Web of Science ®Google Scholar
• Haluska FG, Tsao H, Wu H, et al. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res. 2006;12(7Suppl):2301s–2307s.
   PubMedGoogle Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014;372:30–39.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–451.
   PubMed Web of Science ®Google Scholar
• Puzanov I. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Transl Med. 2015;13(Suppl 1):K8.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Callahan MK, Linette GP, et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM). J Clin Oncol. 2014;32(15_suppl):2511.
   Web of Science ®Google Scholar
• Luke JJ, Hodi FS. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist. 2013;18:717–725.
   PubMed Web of Science ®Google Scholar
• Qin Q, Nan X, Miller T, et al. Complete local and abscopal responses from a combination of radiation and nivolumab in refractory Hodgkin’s Lymphoma. Radiat Res. 2018;190:322–329.
   PubMed Web of Science ®Google Scholar
• Jacquelot N, Roberti MP, Enot DP, et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017;8:592.
   PubMed Web of Science ®Google Scholar
• Richtig G, Hoeller C, Wolf M, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study. PLoS One. 2018;13:e0204729.
   PubMed Web of Science ®Google Scholar
• Balatoni T, Ladányi A, Fröhlich G, et al. Biomarkers associated with clinical outcome of advanced melanoma patients treated with Ipilimumab. Pathol Oncol Res. 2018. DOI:10.1007/s12253-018-0466-9
   PubMedGoogle Scholar
• Carlino MS, Long GV, Schadendorf D, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018;101:236–243.
   PubMed Web of Science ®Google Scholar
• Wagner NB, Forschner A, Leiter U, et al. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. Br J Cancer. 2018;119:339–346.
   PubMed Web of Science ®Google Scholar
• Valpione S, Pasquali S, Campana LG, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med. 2018;16:94.
   PubMed Web of Science ®Google Scholar
• Rohlfs M, Bassett RL, Lacey C, et al. BRAF with or without MEK inhibition plus PD-1 checkpoint blockade for the treatment of metastatic melanoma. J Clin Oncol. 2016;34(Abstract):9548.
   Google Scholar
• Kirchberger MC, Ugurel S, Mangana J, et al. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: results of a retrospective multicentre analysis of 364 patients. Eur J Cancer. 2018;98:10–16.
   PubMed Web of Science ®Google Scholar
• Barcena E, Trinh V, McIntyre SE, et al. Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors. J Clin Oncol 2016;34: Abstract 9546.
   Web of Science ®Google Scholar
• Kakavand H, Jackett LA, Menzies AM, et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol. 2017;30:1666–1676.
   PubMed Web of Science ®Google Scholar
• Grabmeier-Pfistershammer K, Stecher C, Zettl M, et al. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade. Clin Immunol. 2017;183:167–173.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Shoushtari AN, Keohan ML, et al. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus Ipilimumab. Clin Cancer Res. 2017;23:2972–2980.
   PubMed Web of Science ®Google Scholar
• Sioud M, Nyakas M, Sæbøe-Larssen S, et al. Diversification of antitumour immunity in a patient with metastatic melanoma treated with Ipilimumab and an IDO-silenced dendritic cell vaccine. Case Rep Med. 2016;2016:9639585.
   PubMedGoogle Scholar
• Diem S, Hasan Ali O, Ackermann CJ, et al. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother. 2018;67:39–45.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Coughlin LA, Kim J, et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia. 2017;19:848–855.
   PubMed Web of Science ®Google Scholar
• Hopkins AM, Rowland A, Kichenadasse G, et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer. 2017;117:913–920.
   PubMed Web of Science ®Google Scholar
• Balatoni T, Mohos A, Papp E, et al. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. Cancer Immunol Immunother. 2018;67:141.
   PubMed Web of Science ®Google Scholar
• Gambichler T, Brown V, Steuke AK, et al. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis. J Eur Acad Dermatol Venereol. 2018;32:972–977.
   PubMed Web of Science ®Google Scholar
• Mo X, Zhang H, Preston S, et al. Interferon-γ signaling in melanocytes and melanoma cells regulates expression of CTLA-4. Cancer Res. 2018;78:436–450.
   PubMed Web of Science ®Google Scholar
• Jamal R, Lapointe R, Cocolakis E, et al. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. J Immunother Cancer. 2017;5:83.
   PubMed Web of Science ®Google Scholar
• Lin ZP, Zhu YL, Ratner ES. Targeting cyclin-dependent kinases for treatment of gynecologic cancers. Front Oncol. 2018;8:303.
   PubMed Web of Science ®Google Scholar
• Yu W, Li L, Wang G, et al. KU70 inhibition impairs both non-homologous end joining and homologous recombination DNA damage repair through SHP-1 induced dephosphorylation of SIRT1 in adult T-cell leukemia-lymphoma. CellsCell Physiol Biochem. 2018;49:2111–2123.
   PubMed Web of Science ®Google Scholar
• Jiang W, Li Q, Zhu Z, et al. Cancer chemoradiotherapy duo: nano-enabled targeting of DNA lesion formation and DNA damage response. ACS Appl Mater Interfaces. 2018;10:35734–35744.
   PubMed Web of Science ®Google Scholar